Letting these Medicare subsidies expire is the right thing to do

By the Editorial Team · Friday, July 31, 2026

The Trump administration declared that the subsidy program for stand-alone Medicare Part D plans will end this year instead of 2027, reversing a Biden-era policy designed to offset premium increases. This expiration is expected to lead to higher premiums for beneficiaries but aims to reduce growing federal expenditures that have already increased taxpayer costs by billions annually.

The Trump administration announced on Tuesday that a subsidy program supporting stand-alone Medicare Part D prescription drug plans will expire at the end of this year, rather than continuing through 2027 as initially planned. The program, which was introduced under President Joe Biden through administrative action without congressional authorization, originated from provisions in the 2022 Inflation Reduction Act (IRA) that lowered the cap on out-of-pocket drug costs for seniors.

While the policy aimed to reduce seniors’ cost exposure, it did not actually lower overall drug costs. Instead, the financial burden shifted to insurance premiums. To mitigate the impact of premium increases ahead of the 2024 elections, the Biden administration implemented temporary subsidies that provide direct payments to private insurers sponsoring Part D plans. These payments have helped keep premiums relatively stable but have simultaneously transferred more of the cost to the federal government.

Currently, taxpayers cover around 87 percent of Part D premiums, up from approximately three-quarters before the subsidy program. Notably, this increased federal spending comes amid a market where real premiums for stand-alone Part D plans have been on a downward trend since at least 2010, adjusted for inflation. The continued subsidies are estimated to cost nearly $10 billion over 2025 and 2026.

The IRA’s reforms, while lowering seniors’ out-of-pocket costs, led to higher-than-expected expenses overall, which in turn required increased subsidies. Critics argue that these additional taxpayer-funded payments resemble temporary bailouts rather than sustainable health care cost solutions. Similar concerns have been raised regarding enhanced subsidies for Affordable Care Act plans, with some analysts contending that increased federal spending in a market influenced by prior policy changes does not make health care more affordable in the long run.

Supporters of allowing the subsidies to expire contend that restoring cost-sharing for beneficiaries could promote greater cost consciousness within the program. Despite potential premium increases, competition within the Part D market remains robust, allowing seniors to compare and switch to more affordable plans as needed. The Centers for Medicare and Medicaid Services (CMS) estimates the base premium for 2027 will be $41.33, reflecting a more market-driven environment.

The Congressional Budget Office (CBO) reported in February that Medicare spending over the next decade is projected to be $1 trillion higher than previously expected, with a substantial portion of this increase attributed to the IRA’s changes to Part D. Some policymakers argue that the escalating costs cannot be countered solely by increasing taxpayer subsidies.

After the subsidies sunset, the Part D program will still retain more generous benefits than before the IRA’s enactment. Observers emphasize that temporary financial assistance to insurance companies should not become a permanent policy fixture. They suggest that if a program requires ongoing federal bailouts to function effectively, it signals fundamental flaws in the policy rather than a problem with the expiration of temporary support.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.